Quadria Capital

Quadria Capital is a premier healthcare-focused private equity firm in Asia, managing over US$4 billion in assets across 27 investments in South and Southeast Asia, including India, Vietnam, Indonesia, Malaysia, and Singapore. The firm specializes in growth capital investments in small and middle-market companies within the healthcare sector, aiming to create significant and sustainable shareholder value by partnering with exceptional healthcare businesses to enhance their impact and scale, while generating superior returns for investors.

The firm's investment strategy involves taking significant minority and majority stakes in market-leading companies, with a focus on sectors such as healthcare delivery, medical technology, biotechnology, pharmaceuticals, and health technology. Quadria Capital employs a hands-on approach, leveraging its deep domain expertise, operational experience, and industry network to unlock value and drive growth in its portfolio companies.

Quadria Capital has a proven track record of successful investments, including NephroPlus, Asia's largest dialysis network; Maxivision, one of India's fastest-growing eye care chains; and Straits Orthopaedics, a premier manufacturer of orthopedic implants and surgical instruments. The firm's commitment to healthcare transformation in Asia is underscored by its recent closing of Fund III with US$1.07 billion in total commitments, significantly exceeding its original $800 million target, and positioning it as one of the largest dedicated healthcare private equity funds in the region.